Cardiff Oncology
CRDF
83 hedge funds and large institutions have $34.1M invested in Cardiff Oncology in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 15 closing their positions.
439% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $406K
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
17% more capital invested
Capital invested by funds: $29.1M → $34.1M (+$5.02M)
1.85% less ownership
Funds ownership: 29.26% → 27.41% (-1.8%)
8% less funds holding
Funds holding: 90 → 83 (-7)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.05M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$672K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$499K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$358K |
| 5 |
Two Sigma Advisers
New York
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.23M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$368K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$333K |
| 4 |
Millennium Management
New York
|
-$205K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$191K |
CRDF Hedge Fund Activity: Q3 2024 in Review
83 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2024, worth a combined $34.1M — up 17% from $29.1M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CRDF and 8 opened new positions — a net loss of 7 holders — while 23 trimmed existing stakes and 27 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.05M. The largest seller was Assenagon Asset Management, cutting an estimated $2.23M.
- 83 institutional investors held Cardiff Oncology (CRDF) as of Q3 2024, down from 90 in Q2 2024.
- Funds reported $34.1M of Cardiff Oncology stock for Q3 2024, up 17% quarter-over-quarter.
- 8 funds opened new Cardiff Oncology positions in Q3 2024 and 15 closed out, a net change of -7 holders.
- The largest Cardiff Oncology buyer in Q3 2024 was Renaissance Technologies, an estimated $1.05M added.
- The largest Cardiff Oncology seller in Q3 2024 was Assenagon Asset Management, an estimated $2.23M sold.
Based on aggregated 13F filings for Q3 2024.